PARTNERSHIP News
Lunit Joins Global 'Drug Development AI Consortium' to Accelerate Precision Medicine
South Korean AI company Lunit has joined a global consortium of eight companies specializing in AI, digital pathology, and precision diagnostics. The consortium aims to strengthen AI-based pathology a
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Insilico Medicine has formed a multi-target strategic alliance with Bora Pharmaceuticals, a global pharmaceutical manufacturer. The collaboration aims to integrate Insilico's Pharma.AI platform for ta
Insilico Medicine and CMS Ink $177M AI Drug Discovery Pact for CNS
China Medical System Holdings (CMS) has expanded its partnership with Insilico Medicine in an AI-powered drug discovery collaboration valued at up to $177 million. The agreement focuses on a mass-mark
Chai Discovery, Novartis Partner for AI-Driven Antibody Discovery
Chai Discovery has announced a collaboration with Novartis to advance AI-driven antibody discovery, building on previous agreements with Pfizer and Eli Lilly. The partnership aims to leverage Chai's A
ABB Robotics and Roche Partner to Integrate AI-Powered Automation in Labs
ABB Robotics has announced a global collaboration with Roche Diagnostics to develop and launch new robotic solutions for clinical laboratories. This partnership aims to accelerate lab automation and i
ABB Robotics and Roche Partner for AI-Powered Lab Automation
ABB Robotics has announced a global collaboration with Roche Diagnostics to develop and commercialize new robotic solutions for clinical laboratories. This partnership aims to enhance efficiency by in
Takeda Partners with Insilico Medicine in $600M AI Drug Discovery Deal
Takeda has entered a strategic collaboration with Insilico Medicine to utilize its AI-based Pharma.AI platform for the discovery and development of novel drug candidates across Takeda's therapeutic ar
Takeda Enters $600M AI Drug Discovery Pact with Insilico Medicine
Takeda has announced a strategic collaboration with Insilico Medicine, a leader in generative AI for drug discovery, to advance drug candidates across its therapeutic areas. The deal includes a $60 mi
Bayer and Iambic Partner to Advance AI-Driven Drug Discovery
Bayer has announced a research collaboration with Iambic Therapeutics to leverage Iambic's AI-based platform for the discovery of new small molecules. This partnership aims to utilize Iambic's leading
Insilico Medicine Secures $2.5B AI Drug Discovery Partnership
Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, has announced a significant research and development collaboration with SK Biopharmaceuticals. This partnership, valued
Insilico Medicine Secures $2.5B Partnership with SK Biopharma for AI Drug Discovery
Insilico Medicine announced a landmark $2.5 billion global research and development collaboration with SK Biopharmaceuticals at the BIO International Convention 2026. This strategic alliance aims to d
Insilico Medicine & SK Biopharma in $2.5B AI Drug Discovery Deal
Insilico Medicine has partnered with SK Biopharmaceuticals in a research and development collaboration to discover AI-enabled drug candidates for neuroimmune disorders of the central nervous system. T
Insilico, SK Biopharma Partner for $2.5B AI Drug Discovery in Neuroimmune Disorders
Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration with a potential value of up to $2.5 billion, including an $18 million upfront payment. This partnership
Greenstone Biosciences and Intel Partner for AI Drug Discovery
Greenstone Biosciences and Intel Corp. have announced a strategic collaboration to accelerate AI-enabled drug discovery and advance precision medicine. The partnership combines Greenstone's extensive
Greenstone Biosciences and Intel Partner for AI Drug Discovery
Greenstone Biosciences and Intel Corp. have announced a strategic collaboration to advance human-centric drug discovery. This partnership combines Greenstone's large-scale human induced pluripotent st
Axcelead DDP Joins Lilly TuneLab to Advance AI Drug Discovery
Axcelead Drug Discovery Partners (DDP) has announced a collaboration with Lilly TuneLab, Eli Lilly and Company's AI/ML drug discovery platform. This partnership will see Axcelead DDP contribute propri
Boltz, Takeda Partner to Deploy Frontier AI Models for Drug Discovery
Boltz PBC has announced a collaboration with Takeda to integrate its advanced biomolecular AI models, BoltzMol-1 and BoltzProt-1, across Takeda's research organization. This partnership will provide T
AI Transforms Stem Cell Therapy: Cellular Intelligence Partners with Novo Nordisk
AI-native platforms are reshaping stem-cell therapy development, enabling faster design, testing, and manufacturing of living medicines. Cellular Intelligence is leveraging its AI foundation model, tr
Harbour BioMed & BioMap Launch MegaStream TechBio for AI Drug Discovery
Harbour BioMed and BioMap have announced a multi-dimensional, long-term strategic partnership to launch MegaStream TechBio, a new AI-native pipeline company. This collaboration aims to accelerate the
Harbour BioMed and BioMap Launch MegaStream TechBio for AI-Driven Biologics R&D
Harbour BioMed and BioMap have announced a strategic partnership to jointly launch MegaStream TechBio, a new AI-native pipeline company focused on the AI-driven discovery and development of complex bi
Abridge Partners with Eli Lilly and Nvidia to Expand AI Scribe Platform
Abridge, an AI documentation firm, has announced strategic partnerships with pharmaceutical giant Eli Lilly and technology leader Nvidia. Eli Lilly made a strategic investment to support evidence-base
Abridge, Eli Lilly, Nvidia Forge Partnership for AI Clinical Foundation Models
AI documentation firm Abridge has announced a strategic investment from pharmaceutical giant Eli Lilly and a collaboration with Nvidia to develop a foundation model for clinical conversations. This pa
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate RNAi Therapeutics Discovery
Alnylam Pharmaceuticals has announced a strategic collaboration with AI biotech Inceptive Nucleics, valued at up to $2 billion, to accelerate the discovery of RNAi therapeutics. The partnership combin
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
Alnylam Pharmaceuticals has announced a strategic collaboration with Inceptive, valued at up to $2 billion, to accelerate the discovery and development of RNA interference (RNAi) therapeutics using ge
Alnylam Strikes $2B AI Deal with Inceptive for RNAi Drug Discovery
Alnylam Pharmaceuticals has entered a strategic partnership with Inceptive, an AI platform for protein engineering, to accelerate the discovery and optimization of RNA interference (RNAi) therapeutics
NVIDIA, Foxconn, and Taiwan Medical Centers Bring AI to 'Healthy Taiwan'
Foxconn is deploying NVIDIA AI across Taiwan's medical centers for the "Healthy Taiwan" initiative, transitioning from individual AI tools to coordinated AI agent workforces. This includes agentic and
MicroPort NeuroScientific & OYMotion Partner on BCI & Exoskeleton
MicroPort NeuroScientific Corporation has formed a strategic partnership with OYMotion Technologies Co., Ltd. for the deep integration of brain-computer interface (BCI) and exoskeleton robot systems.
Hammerspace and Secuvy AI Expand Partnership in Asia-Pacific
Hammerspace, a high-performance data platform for AI, has announced an exclusive strategic partnership with Secuvy across the Asia-Pacific region. This collaboration aims to provide best-in-class AI d
Anthropic Reportedly In Talks With Microsoft To Use Maia AI Chips
Anthropic is reportedly in discussions with Microsoft to utilize its Maia AI chips as the competition for advanced computing capacity in the artificial intelligence sector intensifies. This potential
Lilly, BMS, Incyte Strike Deals to Keep Biopharma's AI Integration Rolling
Eli Lilly, Bristol Myers Squibb, and Incyte have recently formed new partnerships, further embedding artificial intelligence into their drug development processes. Bristol Myers Squibb partnered with
Incyte expands AI drug discovery pact with Genesis with $120M up front
Incyte has significantly expanded its AI drug discovery partnership with Genesis, committing an $80 million upfront payment and a $40 million equity investment. This deal, valued at over $1 billion wi
QIAGEN and NVIDIA Partner for AI-Driven Drug Discovery Advancement
QIAGEN Digital Insights is integrating NVIDIA's accelerated computing and BioNeMo platform with its curated bioinformatics knowledge to enhance AI in drug discovery. This collaboration aims to help ph
Lilly Partners Profluent for AI-Designed Genetic Medicine Development
Eli Lilly has entered into a multi-program strategic research collaboration with AI company Profluent to develop and commercialize AI-designed site-specific recombinases for genetic medicine. This par
Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine 'holy grail'.
Eli Lilly has entered a strategic partnership with AI-driven biotech Profluent, potentially worth up to $2.25 billion, to advance new DNA editing technologies. This collaboration focuses on developing
HK inno.N Partners Atommerce for AI-Based Obesity Drug Discovery
HK inno.N has signed a joint R&D agreement with Atommerce to develop next-generation AI-based obesity treatments. The collaboration will leverage Atommerce's AI drug design platform 'CANDDIE' to ident
Merck and Google Cloud Partner in $1B AI Enterprise Transformation
Merck and Google Cloud have announced a significant multi-year partnership, valued at up to $1 billion, to integrate an agentic AI platform across Merck's global operations. This collaboration aims to
Tempus AI and Predicta Biosciences Partner for Genomic Assay Expansion
Tempus AI and Predicta Biosciences have announced a commercial partnership to expand access to GenoPredicta, an ultrasensitive whole-genome sequencing assay. This co-branded assay is designed for comp
OpenAI Partners with Novo Nordisk to Accelerate Drug Discovery and Delivery
Artificial intelligence powerhouse OpenAI Group PBC has announced a strategic partnership with pharmaceutical giant Novo Nordisk A/S. This collaboration aims to integrate OpenAI's advanced AI capabili
Noul Partners with US Regenerative Medicine Provider for AI Blood Analysis
AI-based diagnostics company Noul has partnered with U.S. regenerative medicine provider Infinite Medical to apply its AI-powered blood analysis solution, miLab BCM, in stem cell therapy and regenerat
IQVIA and NVIDIA Partner on AI Platform, Expand Collaborations
IQVIA has rolled out its IQVIA.ai platform, a result of its partnership with NVIDIA, and simultaneously acquired drug discovery assets from Charles River Laboratories while expanding research collabor
AI Unlocks Hidden 98% of Human Genome in Major Research Partnership
Sheba Medical Center, Icahn School of Medicine at Mount Sinai, and NVIDIA have initiated a three-year collaboration to harness artificial intelligence and large language models to decode the 98% of th
Regeneron Partners with TriNetX for AI-Driven Drug Discovery and Digital Health
Regeneron Pharmaceuticals has announced a strategic collaboration with TriNetX, including an investment of up to $200 million, to gain exclusive access to TriNetX's network of approximately 300 millio
Flagship Pioneering and AWS Partner to Accelerate AI Drug Discovery
Flagship Pioneering and Amazon Web Services (AWS) have announced a strategic collaboration to accelerate life sciences breakthroughs across Flagship's portfolio companies. The partnership will provide
Eli Lilly Expands Insilico Medicine AI Drug Discovery Deal to $2.75B
Eli Lilly has significantly expanded its partnership with Insilico Medicine, committing up to $2.75 billion for AI-powered drug discovery. This collaboration grants Lilly exclusive worldwide rights to
Eli Lilly Expands $2.75B AI Drug Discovery Partnership with Insilico Medicine
Eli Lilly has significantly expanded its artificial intelligence collaboration with Insilico Medicine in a deal that could reach $2.75 billion. The expanded partnership grants Lilly exclusive global r
Eli Lilly Expands Insilico Medicine AI Drug Discovery Pact to $2.75 Billion
Eli Lilly has broadened its partnership with AI-powered biotech Insilico Medicine, entering a drug discovery and development agreement valued at up to $2.75 billion. The deal includes an upfront payme
Eli Lilly Expands AI Drug Discovery Partnership with Insilico Medicine in $2.75B Deal
Eli Lilly has significantly deepened its collaboration with Insilico Medicine through a new drug discovery and development agreement potentially worth up to $2.75 billion. This partnership grants Lill
Insilico Medicine & Lilly Partner in $2.75B AI Drug Discovery Deal
Insilico Medicine and Eli Lilly and Company have announced a global multi-target research and development collaboration, leveraging Insilico's generative artificial intelligence (AI) platform for drug
Converge Bio Expands AI Antibody Partnership with Purple Biotech
Converge Bio is deepening its collaboration with Purple Biotech on advanced antibody therapeutics, specifically for Purple Biotech's CAPTN-3 tri-specific antibody platform for solid tumors. Converge B
Revvity & Profluent Launch AI-Enhanced Base Editing Access Program
Revvity and Profluent have partnered to introduce an AI-enhanced Base Editing Access Program. This initiative aims to accelerate therapeutic development by providing selected researchers with complime
BioMarin and Deep Genomics Partner on AI for Rare Disease Drug Discovery
BioMarin Pharmaceutical Inc. announced a new strategic partnership with Deep Genomics, an AI-driven drug discovery company. The collaboration aims to leverage Deep Genomics' AI platform to identify an
Insilico Medicine Expands AI-Driven CNS Drug Discovery Partnership
Insilico Medicine, a clinical-stage generative AI biotechnology company, and Tenacia Biotechnology have expanded their AI-driven R&D collaboration for central nervous system (CNS) therapeutics. The ex
Purple Biotech, Converge Bio Partner on AI Tri-Specific Antibody Design
Purple Biotech has announced a collaboration with Converge Bio to utilize advanced generative AI for designing and optimizing its next-generation tri-specific antibody platform for oncology. This part
Purple Biotech Partners with Converge Bio for AI-Driven Antibody Design
Purple Biotech Ltd. has announced a strategic collaboration with Converge Bio to leverage its generative AI platform for the accelerated design and optimization of next-generation tri-specific antibod
Tecan and NVIDIA Partner to Create AI-Driven Laboratories
Tecan and NVIDIA have announced a strategic partnership to integrate AI directly into laboratory workflows, aiming to transform raw laboratory data into actionable insights and improve lab efficiency.
Insilico, ASKA Partner for AI-Driven Gynecological Drug Discovery
Insilico Medicine has announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. to identify novel therapeutic targets for challenging gynecological conditions such as endometrios
Ainnocence calls for global collaboration on AI-driven antibody and vaccine discovery
Ainnocence Inc. is advocating for worldwide collaboration to utilize its generative AI platform for accelerated discovery of antibodies and vaccines targeting infectious diseases. The company's platfo
Science Corp and Neurosoft unite to speed brain-computer care
Science Corporation and Neurosoft Bioelectronics have formed a new partnership to reduce the cost and accelerate the development of brain-computer interface (BCI) therapies. This collaboration aims to
Merck and Mayo Clinic Launch AI-Driven Precision Medicine Lab
Merck and Mayo Clinic have initiated a strategic collaboration to integrate multimodal clinical data with AI, aiming to accelerate drug discovery and target identification. This partnership will utili
Insilico Medicine and Liquid AI Partner for Lightweight AI Drug Discovery Models
Insilico Medicine and Liquid AI have announced a strategic partnership to develop lightweight scientific foundation models for pharmaceutical research. Their collaboration has yielded LFM2-2.6B-MMAI (
Verily and Google Cloud Unite to Boost AI for Biomedical Research
Verily, an Alphabet company focused on life sciences, has announced a strategic partnership with Google Cloud to integrate their AI and machine learning capabilities into biomedical research. This col
Science Corp. & Neurosoft Bioelectronics Partner on BCI Ecosystem
Science Corp. and Neurosoft Bioelectronics have announced a strategic partnership to develop brain-computer interface (BCI) products, aiming to accelerate clinical adoption and reduce development cost
Merck and Mayo Clinic Partner on AI to Accelerate MS Drug Discovery
Merck and Mayo Clinic have announced a research collaboration aimed at utilizing artificial intelligence and large-scale clinical data to expedite drug discovery and development, with an initial focus
Google LLC Partners with Academic Research & Universities Labs on AI-Powered Sequencing Analysis
As the genomics & sequencing ai market heats up — analysts project it will reach $8.3 billion by 2028 — Google LLC has made its move. The company's platform, DeepVariant, deep learning variant caller achieving best-in-class accuracy for germline and somatic snps. DeepVariant is an open-source deep l...
How DNAnexus, Inc. Is Accelerating Diagnostic & Clinical Labs Genomic Insights with AI
For diagnostic & clinical labs operators looking to modernize their genomics & sequencing ai capabilities, DNAnexus, Inc. is pitching a compelling proposition. DNAnexus secure cloud platform for genomic data management, analysis, and collaboration at scale, addressing a market where whole-genome seq...
Theis Lab / Helmholtz Munich (Open Source) Launches Multi-Omics Intelligence Platform for Academic Research & Universities
The single-cell & spatial biology segment is undergoing rapid transformation as enterprises embrace a new reality: long-read sequencing and spatial transcriptomics are transforming multi-omics research. Theis Lab / Helmholtz Munich (Open Source) is positioning itself at the center of this shift with...
CRISPR Therapeutics AG Unveils AI Variant Analysis Engine for Pharmaceutical & Drug Development Genomics
The crispr & gene editing design segment is undergoing rapid transformation as enterprises embrace a new reality: long-read sequencing and spatial transcriptomics are transforming multi-omics research. CRISPR Therapeutics AG is positioning itself at the center of this shift with CRISPR Therapeutics,...
Beam Therapeutics Inc. Unveils AI Variant Analysis Engine for Pharmaceutical & Drug Development Genomics
Beam Therapeutics Inc. has entered the crispr & gene editing design arena with Beam Therapeutics, a platform that precision base editing platform enabling single-letter dna corrections without double-strand breaks. The move positions the company in a market projected to reach $8.3 billion by 2028, w...
Intellia Therapeutics, Inc. Launches Multi-Omics Intelligence Platform for Pharmaceutical & Drug Development
For pharmaceutical & drug development operators looking to modernize their crispr & gene editing design capabilities, Intellia Therapeutics, Inc. is pitching a compelling proposition. Intellia Therapeutics in vivo crispr gene editing delivered systemically to treat genetic diseases at their root cau...
How Verve Therapeutics, Inc. Is Accelerating Pharmaceutical & Drug Development Genomic Insights with AI
Verve Therapeutics, Inc. has entered the crispr & gene editing design arena with Verve Therapeutics, a platform that single-course gene editing medicines that permanently lower cardiovascular disease risk from a single treatment. The move positions the company in a market projected to reach $8.3 bil...
Editas Medicine, Inc. Unveils AI Variant Analysis Engine for Pharmaceutical & Drug Development Genomics
For pharmaceutical & drug development operators looking to modernize their crispr & gene editing design capabilities, Editas Medicine, Inc. is pitching a compelling proposition. Editas Medicine crispr gene editing medicines for ocular, hematologic, and oncologic diseases using cas9 and cas12a, addre...
CRISPOR (Academic Open Source) Launches Multi-Omics Intelligence Platform for Academic Research & Universities
As the crispr & gene editing design market heats up — analysts project it will reach $8.3 billion by 2028 — CRISPOR (Academic Open Source) has made its move. The company's platform, CRISPOR Guide RNA Design Tool, comprehensive crispr guide rna design with integrated off-target prediction and scoring...
Montague Lab, University of Bergen (Academic) Launches Multi-Omics Intelligence Platform for Academic Research & Universities
The crispr & gene editing design segment is undergoing rapid transformation as enterprises embrace a new reality: long-read sequencing and spatial transcriptomics are transforming multi-omics research. Montague Lab, University of Bergen (Academic) is positioning itself at the center of this shift wi...
Synthego Corporation Partners with Biotechnology Startups Labs on AI-Powered Sequencing Analysis
For biotechnology startups operators looking to modernize their crispr & gene editing design capabilities, Synthego Corporation is pitching a compelling proposition. Synthego CRISPR Engineering Platform end-to-end crispr engineering platform from guide rna design through edited cell validation, addr...
How Benchling, Inc. Is Accelerating Biotechnology Startups Genomic Insights with AI
With whole-genome sequencing costs have fallen below $200, enabling population-scale studies, the case for AI-powered crispr & gene editing design has never been stronger. Benchling, Inc. is betting on this trend with Benchling CRISPR Guide Design, a platform that integrated crispr guide design with...
Kim Lab, Institute for Basic Science (Academic) Partners with Academic Research & Universities Labs on AI-Powered Sequencing Analysis
As the crispr & gene editing design market heats up — analysts project it will reach $8.3 billion by 2028 — Kim Lab, Institute for Basic Science (Academic) has made its move. The company's platform, Cas-OFFinder Off-Target Prediction Tool, fast, gpu-accelerated crispr off-target site identification ...
Sentieon Inc. Unveils AI Variant Analysis Engine for Diagnostic & Clinical Labs Genomics
Sentieon Inc. has entered the genomics & sequencing ai arena with Sentieon Genomics Analysis Tools, a platform that fastest and most accurate genomic analysis tools delivering production-grade variant calling at scale. The move positions the company in a market projected to reach $8.3 billion by 202...
Inside Sapio Sciences, LLC's Push to Digitize Pharmaceutical & Drug Development Lab Operations
With 58% of biopharma R&D labs have adopted electronic lab notebooks, the case for AI-powered electronic lab notebooks has never been stronger. Sapio Sciences, LLC is betting on this trend with Sapio Sciences Unified Science Platform, a platform that unified science-aware lims and eln platform purpo...
Inside Dotmatics Limited's Push to Digitize Pharmaceutical & Drug Development Lab Operations
Dotmatics Limited has entered the electronic lab notebooks arena with Dotmatics Scientific Informatics Platform, a platform that connected scientific informatics platform unifying data across the r&d pipeline. The move positions the company in a market projected to reach $3.6 billion by 2028, where ...
Inside Benchling, Inc.'s Push to Digitize Biotechnology Startups Lab Operations
Benchling, Inc. has positioned itself as a significant player in electronic lab notebooks, a segment where enterprises are demanding solutions that deliver measurable results. Cloud-based R&D platform unifying lab notebooks, molecular biology, and data management. Benchling is the leading cloud-nati...
Illumina, Inc. Unveils AI Variant Analysis Engine for Diagnostic & Clinical Labs Genomics
For diagnostic & clinical labs operators looking to modernize their genomics & sequencing ai capabilities, Illumina, Inc. is pitching a compelling proposition. Illumina DRAGEN hardware-accelerated secondary analysis platform for genomic data at clinical-grade speed, addressing a market where whole-g...